Recommended content

T.O. firm co-sponsors psilocybin trial to treat front-line clinicians experiencing COVID-related distress

A Toronto-based biotech company is co-sponsoring a trial to treat front-line clinicians who are experiencing COVID-19 distress with psychedelic-assisted psychotherapy.

Cybin announced the randomized, placebo-controlled trial earlier this week. The study will aim to treat symptoms of depression, anxiety, burnout and post-traumatic stress among front-line doctors, nurses and healthcare professionals.

The trial will be hosted in Seattle and in collaboration with the University of Washington. Dr. Anthony Back, a professor of medicine and founding co-director of the University of Washington Center for Excellence in Palliative Care, will lead the study.

“There is tremendous potential in a collaboration between the University of Washington and Cybin to move the field forward, and this project is an incredibly valuable initial step towards a productive future,” said Dr. Back.

As part of its role in the trial, Cybin developed EMBARK, a transdiagnostic psychotherapy model that can be

Read full article on The Growth Op

Follow us on Instagram or join our Telegram channel

Be first to rate

The Growth Op

More news